MRM1 Antibody

What is MRM1 and why is it a significant research target?

MRM1 (Mitochondrial rRNA Methyltransferase 1) is an essential S-adenosyl-L-methionine-dependent 2-O-ribose methyltransferase that catalyzes the formation of 2-O-methylguanosine at position 1145 (Gm1145) in the 16S mitochondrial large subunit ribosomal RNA (mtLSU rRNA). This modification is universally conserved in the peptidyl transferase domain of the mtLSU rRNA and plays a critical role in mitochondrial function. The significance of MRM1 as a research target stems from its involvement in key mitochondrial pathways, including rRNA processing in both the mitochondrion and rRNA processing in the nucleus and cytosol .

MRM1 has gene annotations related to poly(A) RNA binding and methyltransferase activity. The protein has a calculated molecular weight of 39 kDa, which is consistently observed in experimental applications. Understanding MRM1 function and expression patterns provides insights into mitochondrial biology, translation regulation, and potential roles in various pathological conditions that involve mitochondrial dysfunction .

What applications are MRM1 antibodies validated for?

MRM1 antibodies have been successfully validated for multiple research applications. According to the available data, MRM1 antibodies can be reliably used for Western Blot (WB), Immunohistochemistry (IHC), and Enzyme-Linked Immunosorbent Assay (ELISA) applications . Specifically, positive Western Blot detection has been confirmed in HeLa cells, MCF-7 cells, and SH-SY5Y cells, demonstrating the antibody's utility across different human cell lines .

For IHC applications, MRM1 antibodies have been validated in human ovary cancer tissue. The recommended antigen retrieval protocol involves using TE buffer pH 9.0, though citrate buffer pH 6.0 can be used as an alternative method . The antibody shows cross-reactivity with human, mouse, and rat samples, making it valuable for comparative studies across these species .

What are the recommended dilutions and protocols for using MRM1 antibodies?

Proper dilution of antibodies is critical for experimental success. For MRM1 antibodies, the following dilution ranges are recommended based on application type:

It is important to note that these dilutions serve as a starting point, and researchers should titrate the antibody in their specific testing systems to obtain optimal results. Sample-dependent variations may require adjustment of these parameters .

For Western Blot applications, specific protocols optimized for MRM1 detection are available from manufacturers. Similarly, IHC protocols tailored for MRM1 antibody application can be obtained to ensure consistent and reliable results . Following these validated protocols is recommended, especially for first-time users of MRM1 antibodies.

How should MRM1 antibodies be stored and handled to maintain activity?

Proper storage and handling of antibodies are essential for maintaining their reactivity and specificity. MRM1 antibodies are typically provided in a liquid form, purified through antigen affinity methods, and supplied in PBS buffer containing 0.02% sodium azide and 50% glycerol at pH 7.3 .

For long-term storage, MRM1 antibodies should be kept at -20°C, where they remain stable for up to one year after shipment. Importantly, aliquoting is generally unnecessary for -20°C storage, which simplifies handling. Some preparations may contain 0.1% BSA as a stabilizer, particularly in smaller volumes (e.g., 20μl sizes) .

When working with the antibody, it's advisable to minimize freeze-thaw cycles as these can progressively degrade antibody performance. Allow the antibody to warm to room temperature for at least 30 minutes before opening the vial to prevent condensation that could introduce contaminants or dilute the antibody .

How can cross-reactivity and specificity of MRM1 antibodies be rigorously validated?

Western blot analysis should be performed comparing wild-type samples with MRM1 knockdown or knockout models to confirm band specificity. This approach mirrors the methodology used in validating other protein-specific antibodies, such as MRP1-A23, where comparison with established antibodies (e.g., QCRL1) provided confirmation of specificity . Additionally, researchers should test for cross-reactivity with closely related family members, as demonstrated in MRP1 antibody validation where cross-reactivity with MRP2 was systematically assessed .

For immunohistochemistry applications, specificity can be confirmed through:

• Peptide competition assays, where pre-incubation with the immunizing peptide should abolish specific staining

• Comparison of staining patterns with mRNA expression data from public databases

• Parallel staining with a second antibody raised against a different epitope of MRM1

These rigorous validation steps ensure that observed signals genuinely represent MRM1 rather than non-specific binding or cross-reactions with related proteins.

What are the considerations for generating custom MRM1 antibodies for specialized research applications?

When commercial MRM1 antibodies don't meet specialized research needs, custom antibody generation becomes necessary. This process requires careful planning and consideration of several factors.

Antigen design is the first critical step. For MRM1 antibodies, researchers should identify unique, accessible epitopes that are conserved across species of interest if cross-species reactivity is desired. Based on successful approaches with other proteins, synthetic polypeptides covering the C-terminus of the MRM1 protein can be effective antigens, similar to the approach used for MRP1-A23 antibody generation . Alternatively, researchers could target unique regions identified through sequence alignment of MRM1 with related methyltransferases to ensure specificity.

For antibody production, several methods are available:

• Polyclonal antibody production: Typically performed in rabbits or larger mammals, this approach yields a mixture of antibodies recognizing multiple epitopes on MRM1. While effective for many applications, lot-to-lot variability can be a limitation .

• Monoclonal antibody development: Traditional hybridoma technology involves immunizing mice or rats, followed by B cell extraction, fusion with immortal myeloma cells, and single-cell cloning. Modern approaches have improved this process:

  • "During the cloning step, hybridomas require nutrient-rich media to ensure survival. Modern products like BM Condimed H1 Hybridoma Cloning Supplement eliminate the need for feeder layers or animal serums" .

• Single B cell screening technologies: These newer methods "accelerate monoclonal antibody discovery by circumventing the arduous process of generating and testing hybridomas" and involve "B cell isolation, followed by cell lysis, and sequencing of antibody heavy chain and light chain variable-region genes" .

• Recombinant antibody production: This approach has shown high success rates, with one study reporting "92% success rate for generating mAbs for immuno-MRM using a recombinant B cell cloning approach, which is considerably faster than the traditional hybridoma approach" .

The choice between these methods depends on research requirements, timeline, and resources. For projects requiring absolute consistency across long-term studies, monoclonal or recombinant approaches are preferable despite higher initial costs.

How can MRM1 antibodies be optimized for quantitative proteomics applications?

Optimizing MRM1 antibodies for quantitative proteomics, particularly immunoaffinity enrichment coupled with targeted mass spectrometry (immuno-MRM), requires specific considerations beyond traditional immunoassays.

Immuno-MRM combines the specificity of antibody enrichment with the precision of mass spectrometry for quantitative protein analysis. For MRM1 antibody optimization in this context, researchers should focus on:

• Peptide selection: Identify peptides that are unique to MRM1 (proteotypic), fully tryptic, between 8-22 amino acids in length, and free from known post-translational modifications or polymorphisms according to Swiss-Prot database information . These criteria ensure reliable detection and quantification.

• Antibody development strategy: Generate antibodies specifically targeting the selected tryptic peptides rather than the intact protein. This approach has shown high success rates: "the cross-over success rates for using immuno-MRM monoclonals for Western blotting is 58% and for ELISA is 43%, which compare favorably to cross-over success rates amongst conventional immunoassay technologies" .

• Analytical validation: Subject the optimized immuno-MRM assay to fit-for-purpose analytical validation, including assessment of:

  • Lower limit of detection

  • Linear dynamic range

  • Reproducibility (intra-assay and inter-assay CV%)

  • Selectivity in complex matrices like plasma

• Standardization: Incorporate stable isotope-labeled peptide standards for absolute quantification, ensuring assay reproducibility across experiments and laboratories.

This optimization process enables highly sensitive MRM1 quantification, with successful immuno-MRM assays capable of detecting "≤0.5 fmol peptide per μl of human plasma (≤100 ng/ml protein in plasma)" , providing significantly improved sensitivity over traditional methods.

What troubleshooting strategies address common issues with MRM1 antibody-based experiments?

When working with MRM1 antibodies, researchers may encounter several challenges. The following troubleshooting strategies address common issues:

• High background in Western blots:

  • Increase blocking time or concentration (5% BSA or milk in TBST)

  • Optimize antibody dilution (try the upper end of the recommended range: 1:10000)

  • Increase washing duration and frequency between antibody incubations

  • Consider using different blocking agents if milk protein interferes with detection

• Weak or absent signal in Western blot:

  • Verify MRM1 expression in your sample using published literature

  • Optimize protein extraction protocol for mitochondrial proteins

  • Reduce antibody dilution (try 1:2000 as starting point)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Ensure proper antigen retrieval for fixed samples

• Multiple bands or unexpected molecular weight:

  • Compare observed molecular weight to expected 39 kDa

  • Test positive controls (HeLa, MCF-7, or SH-SY5Y cells)

  • Consider post-translational modifications or isoforms

  • Validate specificity with siRNA knockdown

• Inconsistent IHC staining:

  • Optimize antigen retrieval (try both recommended methods: TE buffer pH 9.0 and citrate buffer pH 6.0)

  • Test multiple antibody dilutions within the 1:50-1:500 range

  • Ensure consistent fixation protocols

  • Include positive control tissues (human ovary cancer tissue)

• Cross-reactivity issues:

  • Perform peptide competition assays to confirm specificity

  • Use knockout/knockdown controls when available

  • Test for reactivity with closely related proteins

By systematically applying these troubleshooting approaches, researchers can optimize experimental conditions for reliable MRM1 detection and quantification across different applications.

How can MRM1 antibodies be applied in multiplex immunoassays with other mitochondrial markers?

Developing multiplex immunoassays that include MRM1 alongside other mitochondrial markers requires careful planning to avoid antibody cross-reactivity and signal interference. This approach can provide comprehensive insights into mitochondrial biology and dysfunction.

For successful multiplexing with MRM1 antibodies, consider these methodological steps:

• Antibody selection: Choose MRM1 antibodies raised in different host species than antibodies against other mitochondrial targets. For example, if using the rabbit polyclonal MRM1 antibody (16392-1-AP) , select mouse monoclonal antibodies for other targets to enable species-specific secondary antibody detection.

• Fluorophore selection: When designing multiplex immunofluorescence assays, select fluorophores with minimal spectral overlap. Typical combinations might include:

  • MRM1 (rabbit primary): Anti-rabbit AlexaFluor 488 (green)

  • Mitochondrial marker 1 (mouse primary): Anti-mouse AlexaFluor 594 (red)

  • Mitochondrial marker 2 (goat primary): Anti-goat AlexaFluor 647 (far red)

• Sequential immunostaining: For particularly challenging multiplexing, consider sequential rather than simultaneous staining:

  • Apply first primary antibody, detect with labeled secondary

  • Strip or block remaining activity

  • Apply second primary antibody, detect with differently labeled secondary

  • Repeat as needed for additional markers

• Validation controls: Always include single-stained controls to verify specificity and absence of bleed-through between channels.

• Colocalization analysis: Use appropriate image analysis software to quantify colocalization between MRM1 and other mitochondrial markers, applying statistical methods like Pearson's or Mander's coefficients for quantification.

This multiplexing approach enables researchers to examine MRM1 in the context of other mitochondrial components, providing insights into functional relationships that wouldn't be apparent from single-marker studies.

What considerations should be taken when using MRM1 antibodies for comparative studies across different species?

When designing comparative studies of MRM1 across species, researchers must ensure that the selected antibody can reliably detect orthologous proteins. While the search results indicate that some MRM1 antibodies show reactivity with human, mouse, and rat samples , several methodological considerations can optimize cross-species applications:

• Sequence homology assessment: Before selecting an antibody, analyze the epitope sequence conservation across target species. For MRM1, examine the conservation of the immunogen sequence (such as the fusion protein Ag9483 mentioned in the search results) . Higher sequence identity at the epitope region correlates with better cross-reactivity.

• Validation in each species: Even when manufacturers report cross-reactivity, independent validation in each species is essential:

  • Confirm the expected molecular weight, which may vary slightly between species

  • Verify cellular/tissue localization patterns are consistent with expected mitochondrial distribution

  • Include positive control samples from each species in parallel experiments

• Optimization for each species: Different species may require distinct experimental conditions:

  • Adjust antibody concentrations (potentially higher dilutions for species with highest homology to the immunogen)

  • Modify incubation times and temperatures

  • Adapt blocking reagents to minimize species-specific background

• Consider generating cross-reactive antibodies: If available antibodies don't adequately detect MRM1 across your species of interest, consider custom antibody generation specifically designed for cross-reactivity. This approach was successful for MRP1, where "MRP1-A23 also detected both rat and mouse MRP1. No cross-reactivity was observed with either human or mouse MRP2 while MRP1-A23 weakly cross-reacted with rat MRP2" .

• Data interpretation: When analyzing results, account for species-specific differences in MRM1 expression patterns, post-translational modifications, and interactions with other proteins. These biological variations must be distinguished from technical variations in antibody performance.

By carefully addressing these considerations, researchers can conduct robust comparative studies of MRM1 across species, revealing evolutionarily conserved and divergent aspects of its function.

How are MRM1 antibodies being used in research on mitochondrial dysfunction and disease models?

MRM1 antibodies are becoming valuable tools in investigating mitochondrial dysfunction across various disease models. As a methyltransferase involved in mitochondrial ribosome biogenesis, MRM1's expression and localization patterns can provide insights into mitochondrial stress responses and adaptive mechanisms.

In neurological disease models, MRM1 antibodies can be applied to examine changes in mitochondrial rRNA methylation patterns that may affect translation efficiency and organelle function. This is particularly relevant given that mitochondrial dysfunction is implicated in neurodegenerative conditions. Similar research approaches have been applied to other mitochondrial proteins; for example, studies have shown that "bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1)" , suggesting complex relationships between cellular stress responses and mitochondrial protein regulation.

For cancer research, MRM1 antibodies enable investigation of metabolic adaptations in tumor cells. The validated detection of MRM1 in cancer cell lines like HeLa and MCF-7 provides a foundation for studying how cancer cells might alter mitochondrial rRNA modification to support their altered energy requirements. This parallels findings with other proteins, where "membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT" , highlighting the prognostic significance of such markers.

Methodologically, researchers are combining MRM1 antibody-based detection with functional assays to correlate protein expression with mitochondrial respiration, translation efficiency, and response to stressors. These integrated approaches provide a more comprehensive understanding of how changes in MRM1 levels or activity contribute to disease pathophysiology.

What are the latest developments in MRM1 antibody technology for super-resolution microscopy?

Super-resolution microscopy techniques have revolutionized our ability to visualize subcellular structures beyond the diffraction limit, offering unprecedented insights into mitochondrial organization. Adapting MRM1 antibodies for these advanced imaging modalities requires specific optimizations.

For Stimulated Emission Depletion (STED) microscopy, researchers are developing directly-labeled MRM1 antibodies using small organic fluorophores optimized for STED, such as ATTO 647N or Abberior STAR 635P. These direct labeling approaches minimize the distance between the fluorophore and target, enhancing resolution compared to secondary antibody detection methods.

For Single-Molecule Localization Microscopy (SMLM) techniques like STORM and PALM, MRM1 antibodies are being coupled with photoswitchable fluorophores. These approaches enable precise localization of individual MRM1 molecules, revealing their distribution within mitochondrial subcompartments at nanometer-scale resolution.

The latest methodological developments also include:

• Expansion microscopy compatibility: Protocols for physically expanding fixed samples while maintaining MRM1 antibody labeling, effectively improving resolution by enlarging the specimen itself.

• Correlative light and electron microscopy (CLEM): Workflows that combine MRM1 immunofluorescence with electron microscopy, providing context for protein localization within the detailed ultrastructure of mitochondria.

• Live-cell compatible nanobodies: Development of small antibody fragments derived from heavy-chain-only antibodies that can penetrate living cells for dynamic imaging of MRM1.

• Multiplexed super-resolution imaging: Methods for visualizing MRM1 alongside other mitochondrial markers at super-resolution, using sequential labeling and imaging or spectrally resolved fluorophores.

These advanced imaging approaches are revealing new insights into MRM1's precise localization within mitochondria and its spatial relationships with other components of the mitochondrial translation machinery.

What are the emerging trends in MRM1 antibody development and application?

The field of MRM1 antibody technology continues to evolve, with several emerging trends poised to enhance research capabilities. Recombinant antibody production is gaining prominence, offering advantages in reproducibility and customization. As demonstrated in related antibody development efforts, "the success rate (92%) for generating mAbs for immuno-MRM using a recombinant B cell cloning approach" significantly outperforms traditional methods and provides a faster development timeline .

Integration of MRM1 antibodies with advanced proteomics approaches represents another important trend. Immuno-MRM assays combining antibody enrichment with mass spectrometry detection enable highly sensitive and specific quantification of MRM1 in complex biological samples. These assays can achieve detection limits of "≤0.5 fmol peptide per μl of human plasma" , facilitating studies of MRM1 in clinical specimens where protein abundance may be low.

Increasingly, researchers are developing application-specific MRM1 antibodies optimized for particular techniques rather than relying on general-purpose reagents. This specialization ensures optimal performance in challenging applications like super-resolution microscopy, FACS, or chromatin immunoprecipitation.

Finally, there is growing emphasis on comprehensive validation and data sharing. Initiatives similar to the "Clinical Proteomic Tumor Analysis Consortium's (CPTAC) Antibody and Assay Portals" are promoting transparency in antibody characterization and encouraging researchers to share detailed validation data, ultimately improving reproducibility across the field.

How might advances in antibody engineering impact future MRM1 research?

Advances in antibody engineering are poised to transform MRM1 research by providing more specific, versatile, and functional reagents. Several technological developments will likely shape this evolution:

• Site-specific antibodies for post-translational modifications: Engineered antibodies specifically recognizing modified forms of MRM1 (phosphorylated, acetylated, etc.) will enable research into regulatory mechanisms controlling its activity. These highly specific reagents will facilitate understanding of how MRM1 function is modulated under different cellular conditions.

• Intrabodies and nanobodies: The development of smaller antibody formats that maintain specificity while functioning within living cells will enable real-time tracking of MRM1 localization and dynamics. These tools will provide unprecedented insights into MRM1 behavior during mitochondrial stress responses or cell cycle progression.

• Bifunctional antibodies: Engineered antibodies that simultaneously bind MRM1 and another molecule (either another protein or a reporter) will enable novel applications like proximity labeling or induced degradation. These approaches will help identify MRM1 interaction partners and assess the consequences of its acute depletion.

• Humanized antibodies for therapeutic applications: If MRM1 emerges as a therapeutic target, humanized antibodies could be developed for potential clinical applications, building on the foundation of research-grade reagents.

• Machine learning-guided antibody optimization: Computational approaches to predict epitope accessibility and antibody binding properties will accelerate the development of high-performance MRM1 antibodies with reduced experimental iteration.